Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacodynamics > chapter 2 > Flashcards

chapter 2 Flashcards

1
Q

why is verapamil a better choice for managing hypertension in a tachycardic and tachypneic patient with brochial asthma?

A

Verapamil may be a better option for individuals with certain comorbidities, such as asthma or chronic obstructive pulmonary disease (COPD), as it doesn’t have the same potential to worsen bronchoconstriction as propranolol, a beta-blocker.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

“action of the drug on the body”

A

Pharmacodynamics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
  1. specific molecules in a biologic system with which drugs interact to produce changes in the function of the system
  2. selective
  3. modifiable
A

Receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q
  1. Receptors largely determine the quantitative relations between dose or concentration of drug and pharmacologic effects.
  2. Receptors are responsible for selectivity of drug action.
  3. Receptors mediate the actions of pharmacologic agonists and antagonists.
A

The Receptor Concept

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Natural ligands are presently unknown, may be useful targets in the future for drug development

A

Orphan Receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

molecules that translate the drug into a change in cellular activity
receptor interaction
- E.g. enzymes - adenylyl cyclase

A

Effector

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

best characterized drug receptors, mediate the actions of endogenous chemicals such as neurotransmitters, autacoids, hormones e.g. GABA receptors (benzodiazepines)

A

Regulatory proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

receptor for antineoplastic drug methotrexate

A

dihydrofolate reductase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

receptor for statins

A

HMG-Coa reductase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

drug receptor for Digitalis

A

Transport protein (Na/K atpase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

drug receptor for tubulin (colchicine)
-antiinflammatory

A

Structural proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

useful drug targets for cocaine ang psychostimulants

A

Dopamine transporter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

useful drug targets for norepinephrine and serotonin (antidepressants)

A

Na/K ATPase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

overall transduction process that links drug occupancy of receptors and pharmacologic response

A

Coupling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Receptor that does not bind drug when the drug concentration is sufficient to produce maximal effect; present if ~ > EC50

A

Spare receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Specific region of the receptor molecule to which the drug binds

A

Receptor site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

A molecule to which a drug may bind without changing any function

A

Inert binding molecule or site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

eg. psychoactive drugs
-bind to diff site of a receptor causing diff response
-affect interaction of drug and receptor

A

Allosteric Modulators

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

As dose increase, the increment diminishes

A

EC50

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

A drug that activates its receptor upon binding

A

Agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

An agonist that activates the same receptor as other drugs in its group but also causes additional downstream effects that are not seen with other agonists in the group

A

Biased agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

A drug that binds to the receptor without activating it and thereby prevents activation by an agonist

A

Pharmacologic antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

A pharmacologic antagonist that can be overcome by increasing the concentration of agonist

A

Competitive antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

A pharmacologic antagonist that cannot be overcome by increasing agonist concentration

A

Irreversible antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

A drug that counters the effects of another by binding to a different receptor and causing opposing effects

A

Physiologic antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

A drug that counters the effects of another by binding the agonist drug (not the receptor)

A

Chemical antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

A drug that binds to a receptor molecule without interfering with normal agonist binding but alters the response to the normal agonist

A

Allosteric agonist, antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

A drug that binds to its receptor but produces a smaller effect (Emax) at full dosage than a full agonist

A

Partial agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Activity of a receptor absence of an agonist ligand

A

Constitutive activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

A drug that binds to the nonactive state of a receptor molecule and decreases constitutive activity

A

Inverse agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

opiod agonists

A

morphine
methadone
fentanyl
hydromorphone
meperidine
oxycodone
sufentanil, alfentanil, remifentanil
codeine
hydrocodone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

like morphine but higher potency

A

hydromorphone, oxymorphone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

dose dependent analgesia

A

oxycodone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

like fentanyl but shorter duration if action

A

sufentanul, alfentanil, remifentanil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

less efficacious than morphone, can antagonize strong agonist

A

codeine
hydrocodone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

lagpata nlng table sa ppt ka opioids ahhahahaha

A

mwa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

A graph of the increasing response to increasing drug concentration or dose

A

Graded dose-response curve

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

A graph of the increasing fraction of a population that shows a specified response at progressively increasing doses

A

Quantal dose-response curve

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

in graded dose the concentration that causes 50% of the maximal effect. In quantal dose the conc. that causes a specified response in 50% of the population under study

A

EC50

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

The concentration of drug that binds 50% of the receptors in the system

A

Kd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

in graded dose response curves, the dose that causes a specified toxicity. In quantal dose
response in 50% of the population under study
response curves, the dose that causes 50% of the

A

TD50

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

the largest effect that can be achieved with a particular drug, regardless of dose, Emax

A

Efficacy, maximal efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

the amount or concentration of drug required to produce a specified effect, usually EC50 or ED50

A

Potency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

T/F
When EC50 is high, it implies that the drug is less potent because it takes a higher concentration of the drug to produce a significant effect.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

T/F
The Emax is a characteristic of the drug and does not change based on the value of EC50.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

T/F
if Emax is reached Increasing the C further is unlikely to significantly increase the observed effect

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

indicates the total concentration of
receptor sites (i.e., sites bound to the drug at infinitely high concentrations of free drug)

A

Bmax

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

(the equilibrium dissociation constant) represents the concentration of free drug at which half-maximal binding

A

Kd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

T/F
If the Kd is low, binding affinity is high

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

T/F

A

The EC50 and Kd may be identical but need not be

51
Q

T/F
the sensitivity of a cell or tissue to a particular concentration of agonist depends only on the affinity of the receptor for binding the agonist

A

False.
the sensitivity of a cell or tissue to a particular concentration of agonist depends not only on the affinity of the receptor for binding the agonist (characterized by the Kd) but also on the degree of spareness—the total number of receptors present compared with the number actually needed to elicit a maximal biologic response.

52
Q

maximal response occurs without occupancy of all receptors because of?

A

spare receptors

53
Q

indicates the total concentration of receptor sites (ie, sites bound to the drug at infinitely high concentrations of free drug) and Kd (the equilibrium dissociation constant) represents the concentration of free drug at which half-maximal binding is observed.

A

Bmax

54
Q

logarithm of the dose or concentration

A

abscissa

55
Q

for this receptor the relationship between drug occupancy and response can be simple because the ion current produced by a drug is often directly proportional to the number of receptors bound

A

ligand-gated ion channels

56
Q

for this receptor the occupancy-response relationship is often more complex because the biologic response reaches a maximum before full receptor occupancy is achieved.

A

those linked to enzymatic signal transduc- tion cascades

57
Q

After treatment with a low concentration of antagonist, the curve is shifted to the

A

right

58
Q

T/F
High agonist concentrations can overcome inhibition by a competitive antagonist. This is not the case with an irreversible (or noncompetitive) antagonist, which reduces the maximal effect the agonist can achieve, although it may not change its EC50.

A

True

59
Q

T/F

A

True
The concentration (C′) of an agonist required to produce a given effect in the presence of a fixed concentration ([I]) of com- petitive antagonist is greater than the agonist concentration (C) required to produce the same effect in the absence of the antago- nist.

60
Q

(the equilibrium dissociation constant) represents the concentration of free drug at which half-maximal binding

A

KD

61
Q

A drug that counters the effects of another by binding to a different receptor and causing opposing effects

A

Physiologic antagonist
e.g. glucocorticoid (hyperglycemia) & insulin

62
Q

A drug that counters the effects of another by binding the agonist drug (not the receptor)

A

Chemical antagonist
e.g. Heparin (negatively charged) & Protamine (positively)

63
Q

example of physiologic antagonist

A

for bradycardia, isoprotenol, B-adrenoreceptor.

increase HR by mimicking sympathetic stimulation of heart

note. atropine a competitive antagonist is better

64
Q

Why do some drugs produce effects that persist for minutes, hours, or even days after the drug is no longer present?

A

if pharmacodynamics:
1. Receptor interaction
2. Downregulation and disensitization
3. Active metabolites (Some drugs are converted into active metabolites that continue to interact with receptors, thereby extending the drug’s effect even after the parent compound is eliminated.)

if Pharmacokinetics: ADME

65
Q

How do cellular mechanisms for amplifying external chemical signals explain the phenomenon of spare receptors?

A

“not all receptors need to be occupied by a drug or ligand to elicit a maximal response”

Spare receptors are receptors that are present in excess of what is needed to produce a maximal cellular response.
In other words, even if only a fraction of the available receptors are occupied by the ligand, the signal amplification mechanisms are capable of producing a full or maximal cellular response.

66
Q

Why do responses to other drugs diminish rapidly with prolonged or repeated administration?

A
  1. Pharmacodynamic Tolerance (One mechanism of pharmacodynamic tolerance is receptor desensitization or downregulation)
  2. Metabolic Tolerance (The body may increase the production of drug-metabolizing enzymes or adapt in other ways to expedite drug clearance)
  3. Tachyphylaxis (is a rapid development of tolerance)
67
Q

Basic mechanisms of transmembrane signaling

A

1.intracellular- receptor
2. transmembrane receptor protein whose intraceccular act. is regulated by extracellular domain
3. transmembrane that use protein tyrosine kinase
4. ligand-gated transmembrane ion channel
5. transmembrane receptor protein that stimulates a GTP transducer protein (G protein)

68
Q

Basic mechanisms of transmembrane signaling

A
  1. lipid-soluble ligand that crosses the membrane and acts on an intracellular
    - receptor
  2. transmembrane receptor protein whose intracellular enzymatic activity is allosterically regulated by a ligand that binds to a site on the protein’s extracellular domain
  3. transmembrane receptor that binds and stimulates an intracellular protein tyrosine kinase
  4. ligand-gated transmembrane ion channel that can be induced to open or closeby the binding of a ligand
  5. transmembrane receptor protein that stimulates a GTP transducer protein (G protein)
69
Q

Family of receptors

A
  1. Intracellular receptors
  2. Enzyme- linked receptors
    -Tyrosine kinase
    -cytokind receptors
  3. Ion Channels
  4. G protein-coupled receptors
70
Q

Types of transmembrane signaling receptors

A

memorize table 2-1 in ppt

71
Q

often induces accelerated endocytosis of receptors from cell surface

lead to down regulation

A

ligand-binding

72
Q

will not immediately relieve symptoms but effects decrease slowly after administration

A

Glucocorticoids

73
Q

Mechanism of activation of the epidermal growth factor (EGF) receptor

A

-tyrosine kinase
- have extracellular hormone binding domain and cytoplasmic domain (proteintyrosine, serine, guanylyl)
-noncovalent
-inhibitors:
1. Extracell: monoconal antibodies (trastuzumab, cetuximab)
2. cytoplasmic: permeant small molecule (gefitinib, erlotinib)

-limited by downregulation bcs of accelerated endocytosis

74
Q

-respond to heterogenous group of peptide ligands
-include growth factor, erythropoietin, interferon
- usedps JAK instead, noncovalentky bonded to STAT

A

Cytokine receptors

75
Q

-often mimic or block natural agonists
- natural ligands are ACH, serotonin, GABA, gkutamate

A

The nicotinic acetylcholine (ACh) receptor -ion channel

76
Q

regulated by phosphorylation and endocytosis

A

ligand gated

77
Q

do not bind neurotransmitters directly, but controlled by membrane potential

bind to a site of receptor dif. from the charged amino acids

A

Voltage gated

78
Q

antiarrythmic
reduce BP w/o antagonizing any known endogenous transmitter

A

verampamil

79
Q

allosteric modulators for CFTR

A

Lumacaftor- deliver to PM
Ivacaftir- channel conductance

-note: ion channel

80
Q

-uses 2nd messagers (camp, calcium ion phosphoinositides)
-produces the phenomenon of spare receptors

A

G protein coupled receptors

81
Q

-largest receptor family
-has 7transmembrane/serpentine
-receptor tail contains serine and threonine
-N (amino): extraceullar
-C (carboxyl): intracellular

A

GPCRs

82
Q

accelerates endocytosis
leades to disensitization of GPCRs

A

B-arrestin

83
Q

are thought to occupy the orthosteric ligand binding site, and differ on receptor conformation

A

Functionally/selective agonist biased-

84
Q

well established 2nd messengers

A

Cyclic Adenosine Monophosphate (cAMP) Phosphoinositides and Calcium
Cyclic Guanosine Monophosphate

85
Q

cAMP-mediated responses

A
  1. mobilization of stored energy
  2. conservation of water by the kidney
  3. Ca2= homeostasis
  4. increased rate and contractile force of the heart muscke
  5. adrenal and sex steroids
  6. smooth muscle
86
Q

mobilization of stored energy

A

breakdown kf carbs in liber, TG3 in fat cells by B adrenomimipetic catecholamines

87
Q

water coservation by kidney

A

vasopressin

88
Q

calcium homeostasis regulated by

A

parathyroid hormones

89
Q

increased rate and contractile force of heart muscle

A

β adrenomimetic catecholamines

90
Q

Regulation of the production of adrenal and sex steroids

A

in reponse to corticotropin or follicule- stimulating hormone

91
Q

Read on The Ca2+ phosphoinosited signaling pathway, cAMP second messenger pathway, and cGMP pathways.

which is faster?

A

cAMP

92
Q

stays on the transmembrane and activates Pk-C, dephosphorylated, deacylated to yield arachidonic acid

A

DAG

93
Q

relase CA2+ into the cytoplasma

A

IP3

94
Q

splits PIP2 into DAG and IP3

A

PLC
phosphoinositide-specific phospholipase C

95
Q

Inyerplay among signaling mechanism

A
  1. Isolation of signaling mechanisms – e.g. calcium signaling in te heart
  2. Reversible phosphorylation in almost all 2nd messengers
96
Q

differing substance specifities

A

Flexible regulation

97
Q

Her2 breast Ca

A

Trastuzumab

98
Q

inhibitor of cytoplasmic tyrosine kinase
treat cylonous leukemia
abl (CML)

A

imatinib

99
Q

related to NO and relaxation of muscle

A

cGMP

100
Q

related to cintracting muscle

A

IP3 and Ca2+ pathway

101
Q

relax muscle

A

cAMP

102
Q

stimulate glucose release

A

IP3, Ca2+ and cAMP

103
Q

fast

A

nicotinic

104
Q

slow

A

muscarinic

105
Q

reduce HR w/o preventing SNS from causing vasoconstriction

A

propanolol

106
Q

acts as antagonist for estrigen in other tissues but an agonist in bones.

inc. bone density and treat bone cancer

A

tamoxiten

107
Q

long term increase in receptor number, may occur when receptor activation is blocked for prolonged periods by pharmacologic antagonists or by denervation.

A

upregulation

108
Q

Long-term reductions in receptor number, may occur in response to
continuous exposure to agonists

A

Downregulation

109
Q

A graph of the increasing response to increasing drug concentration or dose

A

Graded dose response curve

110
Q

A graph of the increasing fraction of a population that shows a specified response at progressively increasing doses

A

Quantal dose response curve

111
Q

relates the dose of a drug required to produce a desired effect to that which produces an undesired effect
“the dose that will heal over the dose that will kill”

A

therapeutic index

112
Q

the range between the minimum toxic dose and the minimum therapeutic dose

A

Therapeutic window

113
Q

unusual; one that is infrequently observed in most patients, usually caused by genetic differences in metabolism of the drug or by immunologic mechanisms (e.g. allergic reactions)

A

isiosyncratic response

114
Q

intensity of effect of a given dose of drug is diminished or increased compared with the effect seen in most individuals

A

Hyporeactive/Hyperreactive response

115
Q

allergic or other immunologic responses to drugs

A

Hypersensitivity

116
Q

responsiveness usually decreases as a consequence of continued drug administratio

A

tolerance

117
Q

responsiveness diminishes rapidly after administration of a drug

A

tachyphylaxis

118
Q

Mechanisms contributing to variation in drug responsiveness

A
  1. Alteration in concentration of drug that reaches the receptor
  2. Variation in concentration of an endogenous receptor ligand
  3. Alterations in number or function of receptors
  4. Changes in components of response distal to the receptor
119
Q

study of genetic factors determining drug response

A

Pharmacogenetics

120
Q

the use of gene sequencing or expression profile data to tailor therapies specific to an individual patient is called

A

Personalized or precision medicine

121
Q

term used by Pharmaceutical advertisements and prescribers implying that the effect in question is insignificant or occurs via a pathway that is to one side of the principal action of the drug; implications are frequently erroneous

A

side effect

122
Q

Beneficial and toxic effects mediated by the same receptor-effector mechanism
(pharmacologic effect – e.g. insulin & hypoglycemia)

A

In the case of insulin therapy for diabetes, the challenge is to achieve glycemic control (lowering blood sugar) without inducing hypoglycemia (excessively low blood sugar).

123
Q

Beneficial and toxic effects mediated by identical receptors but in different tissues or by different effector Pathways (e.g. glucocorticoids)

A

promoting glucose production in the liver, which can be beneficial during times of stress when the body requires additional energy.

Chronic use of glucocorticoids can lead to the loss of bone density, increasing the risk of osteoporosis and fractures.

124
Q

Beneficial and toxic effects mediated by different types of receptors (e.g. opioids)

A

Opioid drugs, like morphine or oxycodone, are commonly used to relieve pain. Their beneficial effects are mainly mediated by binding to specific opioid receptors in the central nervous system.

One of the most significant and potentially life-threatening toxic effects of opioids is respiratory depression. This occurs when opioid drugs bind to opioid receptors in the brainstem,

Pharmacodynamics (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions